Research Analysts Issue Forecasts for ALLO Q1 Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Analysts at Zacks Research issued their Q1 2027 earnings estimates for Allogene Therapeutics in a research note issued to investors on Wednesday, April 2nd. Zacks Research analyst R. Department expects that the company will earn ($0.32) per share for the quarter. The consensus estimate for Allogene Therapeutics' current full-year earnings is ($1.28) per share. Zacks Research also issued estimates for Allogene Therapeutics' FY2027 earnings at ($1.18) EPS.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.34) by $0.06.

Other research analysts have also issued reports about the stock. Canaccord Genuity Group reiterated a "buy" rating and set a $14.00 price target on shares of Allogene Therapeutics in a research note on Friday, March 14th. Citizens Jmp raised Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 target price for the company in a research note on Friday, March 14th. Royal Bank of Canada restated an "outperform" rating and issued a $10.00 price target on shares of Allogene Therapeutics in a research note on Friday, March 14th. Finally, HC Wainwright cut their price objective on Allogene Therapeutics from $9.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday, March 19th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $9.29.

Remove Ads

Allogene Therapeutics Stock Performance

ALLO traded up $0.09 during trading on Friday, hitting $1.45. The stock had a trading volume of 2,840,131 shares, compared to its average volume of 3,189,006. The firm has a market capitalization of $314.38 million, a P/E ratio of -0.90 and a beta of 0.99. Allogene Therapeutics has a twelve month low of $1.25 and a twelve month high of $4.25. The company's 50-day moving average price is $1.78 and its 200 day moving average price is $2.17.

Insider Buying and Selling

In related news, EVP Zachary Roberts sold 27,199 shares of Allogene Therapeutics stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total transaction of $48,414.22. Following the completion of the transaction, the executive vice president now directly owns 488,054 shares in the company, valued at $868,736.12. The trade was a 5.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO David D. Chang sold 46,668 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $1.96, for a total value of $91,469.28. Following the sale, the chief executive officer now owns 5,276,569 shares in the company, valued at approximately $10,342,075.24. This trade represents a 0.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 104,866 shares of company stock worth $194,461 in the last three months. Corporate insiders own 24.30% of the company's stock.

Institutional Trading of Allogene Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Intech Investment Management LLC purchased a new position in Allogene Therapeutics in the 3rd quarter valued at about $116,000. The Manufacturers Life Insurance Company lifted its stake in shares of Allogene Therapeutics by 1.2% during the third quarter. The Manufacturers Life Insurance Company now owns 486,023 shares of the company's stock valued at $1,361,000 after buying an additional 5,642 shares during the period. BNP Paribas Financial Markets boosted its position in Allogene Therapeutics by 541.5% during the third quarter. BNP Paribas Financial Markets now owns 46,374 shares of the company's stock worth $130,000 after acquiring an additional 39,145 shares during the last quarter. Erste Asset Management GmbH purchased a new stake in Allogene Therapeutics in the 3rd quarter worth approximately $91,000. Finally, EP Wealth Advisors LLC raised its holdings in Allogene Therapeutics by 125.6% in the 3rd quarter. EP Wealth Advisors LLC now owns 24,475 shares of the company's stock valued at $69,000 after acquiring an additional 13,625 shares during the last quarter. 83.63% of the stock is currently owned by hedge funds and other institutional investors.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).